Investor Presentaiton
DXd-ADC
Technology
Grand prize for 6th Bioindustry awards
Significant efficacy of ENHERTUⓇ and future potential of DXd-ADC technology
are recognized as breakthrough
Japan Bioindustry Award
バイオインダストリー大賞
DXd-ADC Technology
Daiichi-Sankyo
5 researchers at Daiichi Sankyo received the grand prize for Bioindustry
for "Innovation of New Generation Antibody Drug Conjugate Technology,
DXD-ADC"
➤ This prize is to award an achievement which is expected to have a strong impact on the
development of the fields of bioscience, biotechnology and bioindustry
➤ It is the first time that a company alone receive the prize
➤ General Incorporated Association Japan Bioindustry Association announced award on July 15,
2022
Award recipients:
Toshinori Agatsuma (Head of Oncology Research Laboratories I, Corporate Officer)
Yuki Abe (Head of Oncology Research Laboratories II)
➤ Hiroyuki Naito (Medicinal Chemistry Research Laboratories)
Takashi Nakada (Oncology Research Laboratories I)
Yusuke Ogitani (Oncology Research Laboratories II)
Image is for illustrative purposes only; actual drug to antibody ratio and drug positions may vary.
31View entire presentation